[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Mineralys Therapeutics director reports option exercises and share sales.

Rhea-AI Filing Summary

Mineralys Therapeutics director reports option exercises and share sales. A company director filed a Form 4 showing multiple stock option exercises on November 11–13, 2025 at exercise prices of $10.20 and $12.69 per share, followed by same-day open market sales of the resulting common shares at prices around $42.43–$47.28.

After these transactions, the reporting person held no shares of common stock directly, but continued to hold 34,000 stock options with exercise prices of $10.20 and $12.69, expiring in 2034 and 2035 and vesting in monthly installments.

Insider Trade Summary

Exercise and Sale: 34,675 shares ($1.20M approx. pre-tax spread)

Exercise and Sale 13 txns

Insider Gold Alexander M

Role Director

Sold 34,675 shs ($1.58M)

Approx. gross sale proceeds $1.58M

Approx. exercise cost $379K

Approx. pre-tax spread $1.20M

Type	Security	Shares	Price	Value
Exercise	Stock Option	2,742	$0.00	$0.00
Exercise	Stock Option	10,000	$0.00	$0.00
Exercise	Common Stock	2,742	$10.20	$28K
Exercise	Common Stock	10,000	$12.69	$127K
Sale	Common Stock	12,742	$46.50	$593K
Exercise	Stock Option	6,933	$0.00	$0.00
Exercise	Common Stock	6,933	$10.20	$71K
Sale	Common Stock	5,000	$46.50	$233K
Sale	Common Stock	1,933	$47.2766	$91K
Exercise	Stock Option	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$10.20	$153K
Sale	Common Stock	10,000	$42.4298	$424K
Sale	Common Stock	5,000	$47.0816	$235K

Holdings After Transaction: Stock Option — 42,225 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The stock option vests in 12 monthly installments following the date of grant.
2. F2. The stock option vests in 36 monthly installments beginning on July 13, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 07:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Alexander M

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD, SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		M		15,000	A	$10.2	15,000	D
Common Stock	11/11/2025		S		10,000	D	$42.4298	5,000	D
Common Stock	11/11/2025		S		5,000	D	$47.0816	0	D
Common Stock	11/12/2025		M		6,933	A	$10.2	6,933	D
Common Stock	11/12/2025		S		5,000	D	$46.5	1,933	D
Common Stock	11/12/2025		S		1,933	D	$47.2766	0	D
Common Stock	11/13/2025		M		2,742	A	$10.2	2,742	D
Common Stock	11/13/2025		M		10,000	A	$12.69	12,742	D
Common Stock	11/13/2025		S		12,742	D	$46.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.2	11/11/2025		M			15,000	(1)	02/13/2035	Common Stock	15,000	$0	17,900	D
Stock Option	$10.2	11/12/2025		M			6,933	(1)	02/13/2035	Common Stock	6,933	$0	10,967	D
Stock Option	$10.2	11/13/2025		M			2,742	(1)	02/13/2035	Common Stock	2,742	$0	8,225	D
Stock Option	$12.69	11/13/2025		M			10,000	(2)	06/13/2034	Common Stock	10,000	$0	34,000	D

Explanation of Responses:

1. The stock option vests in 12 monthly installments following the date of grant.

2. The stock option vests in 36 monthly installments beginning on July 13, 2024.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.